Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma

Domenica Lorusso, Romano Danesi, Laura Deborah Locati, Gianluca Masi, Ugo De Giorgi, Angiolo Gadducci, Sandro Pignata, Roberto Sabbatini, Antonella Savarese, Giorgio Valabrega, Claudio Zamagni, Nicoletta Colombo

Open source

DOI: 10.3389/fonc.2023.1232476
Published: 2023-08-07
Container: Frontiers in Oncology
Publisher: Frontiers Media SA
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2023.1232476,
  title = {Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma},
  author = {Domenica Lorusso and Romano Danesi and Laura Deborah Locati and Gianluca Masi and Ugo De Giorgi and Angiolo Gadducci and Sandro Pignata and Roberto Sabbatini and Antonella Savarese and Giorgio Valabrega and Claudio Zamagni and Nicoletta Colombo},
  year = {2023},
  journal = {Frontiers in Oncology},
  doi = {10.3389/fonc.2023.1232476},
  url = {https://doi.org/10.3389/fonc.2023.1232476}
}

RIS

TY  - JOUR
TI  - Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma
AU  - Domenica Lorusso
AU  - Romano Danesi
AU  - Laura Deborah Locati
AU  - Gianluca Masi
AU  - Ugo De Giorgi
AU  - Angiolo Gadducci
AU  - Sandro Pignata
AU  - Roberto Sabbatini
AU  - Antonella Savarese
AU  - Giorgio Valabrega
AU  - Claudio Zamagni
AU  - Nicoletta Colombo
PY  - 2023
JO  - Frontiers in Oncology
DO  - 10.3389/fonc.2023.1232476
UR  - https://doi.org/10.3389/fonc.2023.1232476
ER  -

APA

Lorusso, D., Danesi, R., Locati, L. D., Masi, G., Giorgi, U. D., Gadducci, A., Pignata, S., Sabbatini, R., Savarese, A., Valabrega, G., Zamagni, C., & Colombo, N. (2023). Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma. Frontiers in Oncology. https://doi.org/10.3389/fonc.2023.1232476

Source records

crossref · retrieved 2026-09-26T22:36:48.768Z